THERAPEUTIC VACCINES MARKET ANALYSIS

Market News

Key Developments

Key players in the market are focused on R&D of therapeutic vaccines to expand their market share. For instance, in September 2018, Morphogenesis, Inc., a U.S.-based immunotherapy company and Karolinska Institutet (KI) announced the commencement of a two and a half year collaboration combining Morphogenesis’ gene therapy with the exosome-mediated delivery technology developed by the KI Department of Medicine. This is expected to help to develop patient-specific vaccines for the treatment of several types of cancer.

Moreover, Morphogenesis, Inc. is conducting human trials for its cancer vaccine, ImmuneFX for the treatment of severe cutaneous melanoma. The study is expected to be completed in November 2019.

Similarly, in April 2018, Pfizer Inc. received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its TRUMENBA (Meningococcal Group B Vaccine) for active immunization to prevent invasive disease caused by Neisseria meningitidis group B (MenB) in children ages 1 through 9 years.